<DOC>
	<DOCNO>NCT02496949</DOCNO>
	<brief_summary>ass safety , tolerability，PK efficacy profile two dos ( 600mg,800mg , BID ) Icaritin advance solid tumor patient China</brief_summary>
	<brief_title>A Phase Ib Study Assess Safety Efficacy Oral Icaritin Advanced Solid Tumors</brief_title>
	<detailed_description>Estrogen receptor , ERa36 , predominantly localize plasma membrane cytoplasm mediate membrane-initiated `` nongenomic '' signal pathway . Membrane-initiated estrogen signal link rapid response estrogen generally activate signal pathway like mitogen-activated protein kinase/extracellular signal-regulated kinase ( MAPK/ERK ) , phosphatidylinositol-3-kinase , protein kinase C pathway . Preclinical study demonstrate ERa36 express tumor cell might drive force breast cancer cell proliferation . 40 % breast cancer tumor use consider ER negative also express ERa36 . In former study investigator find 40 % ERa66-positive breast cancer patient express high level ERa36 tumor , subset patient less likely benefit tamoxifen treatment compare ERa66-positive/ERa36-negative tumor . Icaritin newly discover small molecule selective ERa36 modulating capability potential promise new drug treat advance breast cancer hepatocellular carcinoma ( HCC ) target nongenomic pathway . Studies show inhibit growth cancer cell vitro vivo . The investigator complete preclinical pharmacokinetic , pharmacodynamic ( PK &amp; PD ) toxicity study animal move test phase Ib clinical trial .</detailed_description>
	<criteria>Inclusion criterion : 1. age≥18 year old ≤65 2 . The patient advance breast tumors，hepatocellular carcinoma ( HCC ) advance solid tumor patient confirm histologic cytologic diagnosis ER positive subject investigator believe may benefit trial . 3 . Patients advance cancer relapse fail previous standard treatment 4 . 19≤BMI index≤30 5 . No serious heart , liver , lung kidney disease . 6 . .Received least one anticancer treatment ( include chemotherapy , radiotherapy , biological endocrine treatment ) . And last treatment must least four week study enrollment 5 time drug 's halflife time pass . The surgery treatment must three month . 7 . Life expectancy least 12 week . 8 .Patients cooperate observe AE efficacy . 9 . No concurrent anticancer treatment 10 . A sign informed consent must obtain prior perform study specific procedure . 11 . The Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 12 . Female : Women childbearing potential must negative pregnancy test perform 13 . HCC patient : ChildPugh Class A B 1 . Have know hypersensitivity flavonoid drug . 2 . Hepatic : 1 . HCC patient : ALB &lt; 2.8g/dL , TB &gt; 3.0mg/dL , ALT AST &gt; 2.5 time upper limit Normal 2 . Advanced breast tumor advance solid tumor patient : ALB &gt; limit normal , TB &gt; upper limit normal , ALT AST &gt; upper limit Normal Renal : Serum Creatinine &gt; 1.5 time upper limit normal . Blood test : Absolute neutrophil count ( ANC ) &lt; 1.5 × 109/L , Platelet count &lt; 90 × 109/L , Hemoglobin &lt; 9 g/dL . 3 . PT/APTT &gt; 1.25 time upper limit normal . HCC patient : PT &gt; 5 second control 4 . Suffered thrombotic disease . 5 . Serum Ca &gt; upper limit normal . 6 . Not recover toxic effect previous anticancer treatment surgery . 7 . Any serious uncontrollable concomitant systemic disorder ( unstable respiratory disorder , cardiovascular , hepatic kidney disorder . ) active infection influence clinical trial . 8 . CNS metastases invade require treatment unstable status various psychiatric disorder 9 . Malabsorption disease affect drug absorption , distribution , metabolism excretion . 10 . Other concurrent malignancy exception cervical cancer situ squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>